BioGend Therapeutics Co., Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 589,000 compared to TWD 364,000 a year ago. Operating loss was TWD 40.480 million compared to TWD 44.295 million a year ago. Net loss was TWD 44.266 million compared to TWD 40.026 million a year ago. Basic loss per share was TWD 0.48 compared to TWD 0.49 a year ago. For the nine months, sales was TWD 1.074 million compared to TWD 1.105 million a year ago. Operating loss was TWD 104.665 million compared to TWD 120.299 million a year ago. Net loss was TWD 114.379 million compared to TWD 114.260 million a year ago. Basic loss per share was TWD 1.33 compared to TWD 1.41 a year ago.